Design
Preclinical
Authors
Loading...
AT1-Mas hetero-oligomerization may modulate angiotensin II effects; animal data leaves open whether this is a viable cardiovascular therapeutic target.
Key points are not available for this paper at this time.
Kostenis et al. (2005) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: